Understand the clinical evidence for KAPRUVIA®
Overview
November 2024
Learn with Dr Kieran McCafferty about the clinical trials evaluating the efficacy and safety of KAPRUVIA®, including the phase 3 KALM-1 and KALM-2 clinical trials with post-hoc pooled analysis and the KAPRUVIA® open-label safety study
This webinar is CPD accredited.
Download the certificate here once completed.
UK-DFK-2400102 (V2.0)
Key Timestamps
Please use the navigation at the bottom of the video to move easily to different chapters
0:00:05
Chapter 1 - Introduction
0:00:05
Chapter 2 - Agenda
0:01:20
Chapter 3 - What is CKD-associated pruritis? Symptoms, impact on patient pathophysiology
0:12:35
Chapter 4 - Screening, diagnosis, monitoring and treatment
0:25:25
Chapter 5 - Patient case studies
0:47:48
Chapter 6 - Prescribing information and close
Adverse events should be reported. Reporting forms and information for United Kingdom can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Vifor Pharma Ltd.
Tel: +44 1276 853633. E-mail: medicalinfo_UK@viforpharma.com
